Evidence map›Paper›PMID 40364638›Full record

ArticlePsychiatric services (Washington, D.C.)2025

Sensitivity and Specificity of Cognitive Health Screening in a Coordinated Specialty Care Setting.

Alice M Saperstein, Cale N Basaraba, Melanie M Wall, Lisa B Dixon, Ilana Nossel, Iruma Bello, Alice Medalia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alice M SapersteinNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).
Cale N BasarabaNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).
Melanie M WallNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).ORCID 0000-0001-6673-3467
Lisa B DixonNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).
Ilana NosselNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).
Iruma BelloNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).
Alice MedaliaNew York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City (Saperstein, Medalia); New York-Presbyterian Hospital, New York City (Saperstein, Medalia); Department of Psychiatry, Irving Medical Center, Columbia University, New York City (Basaraba, Wall, Dixon, Nossel, Bello).

Funding

OnTrackNY's LearningHealthcareSystemR01MH120597 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BELLO, IRUMA, DIXON, LISA B. · 2019 to 2022
$7.0M
Does the Addition of Cognitive Remediation to Coordinated Specialty Care Services Improve Functional Outcome?R34MH118318 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MEDALIA, ALICE · 2019 to 2022
$724k
NIMH NIH HHS R01 MH120597NIMH NIH HHS R34 MH118318
6 · The paper itself

Abstract

objectiveCognitive health should be addressed as part of routine clinical care for people with schizophrenia spectrum disorder, including those with early psychosis. Providers need an efficient workflow that includes screening tools with adequate sensitivity and specificity to facilitate appropriate cognitive symptom management. This study aimed to examine the utility of a cognitive health screening protocol by analyzing data from 102 participants in OnTrackNY, a specialized network of programs for people experiencing early psychosis.

methodsScreening elicited participants' perceptions of the usefulness of better memory, attention, and critical thinking skills and aimed to detect the presence of cognitive difficulties via participant and clinician reports. The screening protocol's sensitivity and specificity for detecting cognitive impairment, as defined by scores on a brief cognitive assessment, were evaluated.

resultsAbout half the sample had global cognitive impairment, whereas more than 90% demonstrated impairment in at least one cognitive domain. Screening items demonstrated high sensitivity to detect global (≥0.80) and specific cognitive impairment (≥0.74), such that individuals with objectively measured cognitive impairment were likely to be correctly identified, although specificity remained low (≤0.34).

conclusionsThe screening protocol may best be considered as a means to initiate shared decision making for next steps, which may include brief cognitive assessment or more resource-intensive evaluation, and to inform appropriate treatment recommendations.

Indexed as

Cognitive DysfunctionMass ScreeningNeuropsychological TestsPsychotic DisordersSchizophreniaAdultFemaleHumansMaleMiddle AgedSensitivity and SpecificityYoung Adultcognitionprogram evaluationscales/outcome and clinical measurement

Identifiers

PMID40364638
PMCPMC12539601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.